In our previous investigations involving Croatian and Slovenian patients, we did not detect any discernible influence of the CCR5 Δ32 or CTLA-4 +49 A/G polymorphisms on susceptibility to MS or its clinical phenotypes. This evidence concerns the gene CTLA4 and myeloid sarcoma.